Loading stock data…
$1.30-0.02 (-1.46%)
Codexis, Inc.
Codexis, Inc. in the Healthcare sector is trading at $1.31 with a market capitalization of $156M. Wall Street consensus targets $6.14 (7 analysts), implying a +367.1% move over the next 12 months. The stock is currently near its 52-week low of $0.96, remaining 28.5% below its 200-day moving average. On fundamentals, Piotroski 4/9 shows mixed financial quality, Altman Z in the distress zone. The Whystock Score of 40/100 suggests a balanced risk-reward profile.
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $14.91M↓ | $15.25M↓ | $38.91M↑ | $8.60M↓ | $15.33M |
| Gross Profit | $11.40M↓ | $13.18M↓ | $36.87M↑ | $6.14M↓ | $13.23M |
| Operating Income | -$11.23M↓ | -$8.04M↓ | $13.97M↑ | -$18.95M↓ | -$12.86M |
| Net Income | -$12.01M↓ | -$8.70M↓ | $9.60M↑ | -$19.61M↓ | -$13.27M |
Codexis, Inc. provides technology solutions for therapeutics manufacturing, leveraging its proprietary CodeEvolver technology platform to discover, develop, enhance, and commercialize novel enzymes in the United States, Canada, Latin America, Europe,...